Ryvu Therapeutics : Broad oncology targeted therapeutics pipeline includes kinase inhibitor and synthetic lethality programs. Lead programs include SEL24, a first in class PIM/FLT3 kinase inhibitor in Ph 1/2 in AML (partnered with Menarini) and SEL120, a small molecule selective CDK8 inhibitor for leukemias, lymphomas, and solid tumors in Ph 1b in AML and high-risk MDS. Earlier stage pipeline from Cancer Cell Metabolism and Immunometabolism Platform and Immuno-oncology Platform.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll, Pre-Clinical Stage
Disease Space
Immuno-Oncology, Oncology
Finance
Revenues
Industry
Biotechnology, Pharmaceuticals
Listing
Public
Market Cap
100MM - 500MM
Website:
Address:
Bobrzynskiego 14
Park Life Science
Krakow, 30-348
Poland

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Solebury Trout Management Access: SF 2020

San Francisco, CA, United States, January 13 – January 16, 2020

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.